Presented Phase 1 Data on ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society  At the 70th Annual Meeting of the American Epilepsy Society held in December, results from a Phase 1 double-blind, placebo-controlled single ascending dose study involving 32 healthy adults were presented in two  posters entitled, “Neuropsychological Effects of […]

by

StockTwits    Before the market open his morning, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that it had completed enrollment for two Phase 2 trials evaluating its synthetic transdermal cannabidiol (CBD) – a marijuana-derived, non-psychoactive topical gel it’s been developing. The first study will be assessing the drug, called ZYN002, in refractory focal seizures – and the second […]

by

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast […]

by

StockTwits    On Wednesday, Intec Pharma Ltd (NASDAQ:NTEC) announced that it had initiated a Phase 1 clinical program to evaluate its delivery system for marijuana-based therapeutics. The product, which is called the “Accordion Pill,” is a proprietary delivery system for the company’s marijuana-based therapeutics, which are being developed for a number of indications – including pain […]

by

Opko Health Inc. (OPK) announced that it secured orphan drug designation from the U.S. Food And Drug Administration (FDA) for CUR-1916, its novel therapy for treating Dravet Syndrome, a genetic neurological disorder. (See also, Opko Health Outlines 2017 Plans.) The coveted designation offers many benefits and incentives to drug makers, including expedited FDA approval, no […]

by

Say the word “cancer” and most people feel one thing: fear. That’s because, now more than ever, cancer seems to strike across such a broad range of categories — young, old, thin, fat, athletic, stationary and everything in between. With cancer’s prevalence, so too are its “cures,” many of which are wishy-washy in the name […]

by

Shutterstock photo (RTTNews.com) – AVEO Oncology ( AVEO ) has a couple of catalysts coming its way this year. A pre-planned interim futility analysis of phase III trial comparing investigational drug Tivozanib to approved drug Nexavar (sorafenib) in subjects with refractory advanced renal cell carcinoma, dubbed TIVO-3, is expected around mid-year 2017. Enrollment in the […]

by

Shutterstock photo (RTTNews.com) – AVEO Oncology ( AVEO ) has a couple of catalysts coming its way this year. A pre-planned interim futility analysis of phase III trial comparing investigational drug Tivozanib to approved drug Nexavar (sorafenib) in subjects with refractory advanced renal cell carcinoma, dubbed TIVO-3, is expected around mid-year 2017. Enrollment in the […]

by

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

by

March 22, 2017 (Investorideas.com Newswire) Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The […]

by

TORONTO — Researchers at Toronto’s Hospital for Sick Children are poised to begin a clinical trial using cannabis extracts to treat children with severe epilepsy whose seizures can’t be controlled with existing medications. The trial is believed to be the first in Canada to test an oral preparation that contains both CBD and THC, compounds […]

by